28
Mar
2019
Postmortem: 5 Lessons Learned from a Public Benefit Rare Disease Startup
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.